Overview
Patierno's current translational research interests are focused on the genomics molecular biology of cancer disparities, cancer biology, molecular pharmacology and targeted experimental therapeutics to control prostate, breast and lung tumor aggressiveness. He is an internationally recognized expert in cancer control, cancer causation and molecular carcinogenesis, which includes a broad spectrum of laboratory and population level research. Patierno is also actively engaged in cancer health disparities and healthcare delivery research focused on patient navigation, survivorship, community-based interventions, mHealth, implementation sciences, cancer care economics, and policy.
Current Appointments & Affiliations
Charles D. Watts Distinguished Professor of Medicine
·
2023 - Present
Medicine, Medical Oncology,
Medicine
Professor of Medicine
·
2013 - Present
Medicine, Medical Oncology,
Medicine
Professor of Pharmacology and Cancer Biology
·
2013 - Present
Pharmacology & Cancer Biology,
Basic Science Departments
Professor in Family Medicine and Community Health
·
2013 - Present
Family Medicine and Community Health,
Clinical Science Departments
Member of the Duke Cancer Institute
·
2012 - Present
Duke Cancer Institute,
Institutes and Centers
Core Faculty Member, Duke-Margolis Institute for Health Policy
·
2024 - Present
Duke-Margolis Institute for Health Policy,
University Initiatives & Academic Support Units
Recent Publications
Genetic ancestry concordant RNA splicing in prostate cancer involves oncogenic genes and associates with recurrence.
Journal Article NPJ Precis Oncol · January 29, 2025 Black men suffer disproportionately from prostate cancer (PCa) compared to men of other races and ethnicities. Comparing the molecular landscape of PCa among Black and White patients has the potential to identify targets for development of new precision me ... Full text Link to item CiteData from Targeting CaMKK2 inhibits actin cytoskeletal assembly to suppress cancer metastasis
Other · September 16, 2024 <div>Abstract<p>Triple-negative breast cancers (TNBCs) tend to become invasive and metastatic at early stages in their development. Despite some treatment successes in early stage localized TNBC, the rate of distant recurrence remains h ... Full text CiteSupplementary Figures 1-4 and Tables 1-2 from Targeting CaMKK2 inhibits actin cytoskeletal assembly to suppress cancer metastasis
Other · September 16, 2024 <p>Contains Supplementary Figures 1-4, Supplementary Tables 1-2 and legends for Supplementary Videos 1-4</p> ... Full text CiteRecent Grants
Duke University Program in Environmental Health
Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2019 - 2029The Duke Preparing Research scholars In bioMEdical sciences (PRIME): Cancer Research Program
ResearchPreceptor · Awarded by National Cancer Institute · 2023 - 2028Duke Training Grant in Digestive Diseases and Nutrition
Inst. Training Prgm or CMEPreceptor · Awarded by National Institutes of Health · 1988 - 2027View All Grants
Education, Training & Certifications
University of Texas Medical School, Houston ·
1985
Ph.D.
University of Connecticut ·
1981
B.S.